跳至主要内容
临床试验/NCT00738842
NCT00738842已完成1 期

A Randomised, Double-Blind, Two-Period Crossover Study to Assess the Effect of AZD6140 on Uric Acid Levels in Healthy Male Volunteers

AstraZeneca0 个研究点目标入组 24 人开始时间: 2008年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
24
主要终点
The effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

研究概览

简要总结

This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Normal physical examination, vital signs, electrocardiogram (ECG) and laboratory values (unless the investigator considers an abnormality not to be clinically significant)
  • Normal laboratory tests at screening
  • Non-smoker (no cigarette/tobacco use for at least 6 months)

排除标准

  • Personal or family history of gout, gouty arthritis, or renal stones

研究组 & 干预措施

1

Experimental

干预措施: AZD6140 (Drug)

2

Placebo Comparator

干预措施: Placebo to match AZD6140 (Drug)

结局指标

主要结局

The effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.

时间窗: Levels or certain chemicals in subjects' blood and urine will be measured at scheduled times during the first 7 days of the study.

次要结局

  • The blood levels of AZD6140 in various subjects on the same diet.(following dosing during the first 5 days of the study)
  • The effect of taking AZD6140 on the levels of certain hormones in urine(during the first 5 days of the study)

研究者

发起方
AstraZeneca
申办方类型
Industry

相似试验